SPRB

#3695
Spruce Biosciences, Inc. - Common Stock
60.7 8 USD
-0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
60.78
60.78
Jahresspanne
7.26
240.00
Tagesänderung
-3.98%
Monatliche Änderung
+41.32%
6 month change
+12.85%
Jahresänderung
+452.55%
Vorheriger Schlusskurs
63.3 0
Open
60.7 8
Tief
60.7 8
Hoch
60.7 8
Volumen
5
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
SPRUCE BIOSCIENCES, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
SPRUCE BIOSCIENCES, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
SPRUCE BIOSCIENCES, INC. current report, Q1 FY2026
8-K

SPRUCE BIOSCIENCES, INC. current report, Q2 FY2026

Full document

Business Context and Reporting Period

Spruce Biosciences, Inc. (SPRB) filed a Form 8-K on May 13, 2026, to announce financial results for the first quarter ended March 31, 2026. The filing incorporates a press release (Exhibit 99.1) containing the full details of the results and corporate updates.

Key Financial Metrics

  • Cash and Cash Equivalents: $107.3 million as of April 30, 2026.
  • Revenue, Profit, and Margins: The filing text does not provide specific values for revenue, net income, operating margins, or cash flow for the quarter.
  • Debt and Liquidity: Beyond the preliminary cash balance, the filing text does not provide specific data on debt levels or other liquidity metrics.

Material Changes

The filing text does not provide specific comparative data to quantify material changes in financial performance versus the prior comparable period. Investors must refer to the incorporated press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.

Guidance, Outlook, and Risks

  • Preliminary Nature of Data: The reported cash balance of $107.3 million is a preliminary, unaudited estimate subject to change upon completion of financial statement closing procedures.
  • Management Commentary: The filing references corporate updates in the press release but does not detail specific guidance or outlook figures within the 8-K text itself.
  • Legal Disclaimer: The information furnished is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for detailed Q1 2026 revenue, net loss, and operating expense figures.
  • Verify the final audited cash balance once the Q1 2026 financial statements are officially filed, as the $107.3 million figure is preliminary.
  • Check for any updates on the company's burn rate or runway provided in the full press release.
  • Confirm if the company has issued specific forward-looking guidance for the remainder of 2026 in the referenced exhibit.

Nachrichten